摘要
目的 通过对恶性高血压患者血清及尿液中补体因子H(CFH)的半定量分析,探讨CFH在恶性高血压发病中的作用及其临床意义.方法 选取恶性高血压肾损害患者18例,原发性高血压患者17例以及同期健康查体的正常人16例(对照组).采用双抗体夹心酶联免疫吸附(ELISA)法测定血清及尿液中CFH的浓度,同时收集临床生化及尿蛋白等临床指标.结果 恶性高血压患者血清及尿液CFH均明显高于原发性高血压组及对照组,差异有统计学意义(P<0.05),原发性高血压组与对照组比较差异无统计学意义(P>0.05);恶性高血压组患者血清CFH水平与肌酐、尿液CFH、尿蛋白浓度呈正相关(r=0.786,P<0.01;r=0.508,P<0.05;r =0.705,P<0.01).结论 恶性高血压患者CFH可能参与其肾损伤的病理过程.
Objective To investigate the role of complement factor H (CFH) on the pathogenesis of malignant hypertension and its clinical significance in patients with malignant hypertension. Methods We measured the level of CFH in the serum and urine, using double antibody sandwich enzyme-linked im- munosorbent assay (ELISA) in 18 patients with malignant hypertension, 17 patients with hypertension, and 16 normal controls. Results The level of CFH in serum and urine in patients with malignant hypertension was significantly higher than that in patients with hypertension and normal control group, the difference was statistically significant( P 〈0.05 ). The level of CFH in serum was positively correlated with the level of serum creatinine, CFH in urine and the concentration of Urine protein specifically (r = 0. 786, P 〈 0.01 ; r=0. 508,P〈0. 05;r=O. 705,P〈0. 01). Conclusion Complement factor H might play a role in the pathogenesis of kidney injury in patients with malignant hypertension.
出处
《临床内科杂志》
CAS
2014年第11期745-747,共3页
Journal of Clinical Internal Medicine
基金
山东省自然科学基金资助项目,青岛市科技局应用基础研究项目
关键词
恶性高血压
补体
Malignant hypertension
Complement
Complement factor H